DE69841711D1 - Modulator der menschlichen mastzellaktivierung - Google Patents

Modulator der menschlichen mastzellaktivierung

Info

Publication number
DE69841711D1
DE69841711D1 DE69841711T DE69841711T DE69841711D1 DE 69841711 D1 DE69841711 D1 DE 69841711D1 DE 69841711 T DE69841711 T DE 69841711T DE 69841711 T DE69841711 T DE 69841711T DE 69841711 D1 DE69841711 D1 DE 69841711D1
Authority
DE
Germany
Prior art keywords
mast cell
purinoceptors
human
activation
atp binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841711T
Other languages
German (de)
English (en)
Inventor
Amir Pelleg
Edward B Schulman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duska Scientific Co
Original Assignee
Duska Scientific Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duska Scientific Co filed Critical Duska Scientific Co
Application granted granted Critical
Publication of DE69841711D1 publication Critical patent/DE69841711D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Amplifiers (AREA)
DE69841711T 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung Expired - Lifetime DE69841711D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4146197P 1997-03-25 1997-03-25
PCT/US1998/005922 WO1998042353A1 (en) 1997-03-25 1998-03-24 Modulation of human mast cell activation

Publications (1)

Publication Number Publication Date
DE69841711D1 true DE69841711D1 (de) 2010-07-22

Family

ID=21916643

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841711T Expired - Lifetime DE69841711D1 (de) 1997-03-25 1998-03-24 Modulator der menschlichen mastzellaktivierung

Country Status (9)

Country Link
US (2) US6372724B1 (https=)
EP (1) EP1011686B9 (https=)
JP (1) JP2001518118A (https=)
AT (1) ATE470441T1 (https=)
AU (1) AU741713B2 (https=)
CA (1) CA2288821C (https=)
DE (1) DE69841711D1 (https=)
DK (1) DK1011686T3 (https=)
WO (1) WO1998042353A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1011686B9 (en) * 1997-03-25 2011-02-09 Duska Scientific Co Modulation of human mast cell activation
CA2374002A1 (en) * 1999-06-18 2000-12-28 Alcon Laboratories, Inc. Topical ophthalmic mast cell stabilizers for treating allergic eye diseases
GB9916757D0 (en) * 1999-07-17 1999-09-15 Glaxo Group Ltd Method
WO2001071342A2 (en) * 2000-03-23 2001-09-27 Novartis Ag Identification of mast cell/basophil activation inhibitors
WO2002055497A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
EP1351935A1 (en) * 2001-01-15 2003-10-15 Glaxo Group Limited Aryl piperidine derivatives as inducers of ldl-receptor expression
WO2002055496A1 (en) * 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
KR20050043761A (ko) * 2001-11-06 2005-05-11 인스파이어 파마슈티컬스 인코퍼레이티드 염증성 질환의 치료 또는 예방 방법
AU2003222225A1 (en) * 2002-02-20 2003-09-09 Incyte Corporation Receptors and membrane-associated proteins
WO2004015396A2 (en) * 2002-08-13 2004-02-19 Incyte Corporation Cell adhesion and extracellular matrix proteins
US20070219353A1 (en) * 2002-09-03 2007-09-20 Incyte Corporation Immune Response Associated Proteins
WO2004033636A2 (en) * 2002-10-04 2004-04-22 Incyte Corporation Protein modification and maintenance molecules
US20070009886A1 (en) * 2002-11-12 2007-01-11 Incyte Corporation Carbohydrate-associated proteins
AU2003295462A1 (en) * 2002-11-13 2004-06-03 Incyte Corporation Lipid-associated proteins
WO2004048550A2 (en) * 2002-11-26 2004-06-10 Incyte Corporation Immune response associated proteins
WO2004098539A2 (en) 2003-04-30 2004-11-18 Incyte Corporation Kinases and phosphatases
JP2008507368A (ja) * 2004-07-22 2008-03-13 デュスカ サイエンティフィック カンパニー 肺疾患を診断、モニタリングおよび治療するための方法
DK2407484T3 (en) 2005-06-24 2016-09-05 The Walter And Eliza Hall Inst Of Medical Res Therapeutic pro-apoptotic BH3-like molecules, and methods of generating and / or selecting those
GB0601058D0 (en) * 2006-01-19 2006-03-01 Univ Southampton Mast Cell Carboxypeptidase As A Marker For Anaphylaxis And Mastocytosis
AU2008224883A1 (en) * 2007-03-14 2008-09-18 Sierra Molecular Corporation Compositions, systems, and methods for preservation and/or stabilization of a cell and/or macromolecule
US10517839B2 (en) * 2008-06-09 2019-12-31 Cornell University Mast cell inhibition in diseases of the retina and vitreous
WO2014066830A1 (en) 2012-10-25 2014-05-01 Department Of Veterans Affairs Composition and methods for the prevention and treatment of diet-induced obesity
US10614684B2 (en) 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53148539A (en) * 1977-05-30 1978-12-25 Fujisawa Pharmaceut Co Ltd Antiallergic agnet
US5158940A (en) * 1990-02-14 1992-10-27 The United States Government As Represented By The Secretary, Dhhs Use of suramin to treat rheumatologic diseases
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
WO1995033048A2 (en) * 1994-05-27 1995-12-07 Glaxo Group Limited P2x receptors (purinoceptor family)
US5733916A (en) 1995-03-24 1998-03-31 The Trustees Of The University Of Pennsylvania Prevention and treatment of ischemia-reperfusion and endotoxin-related injury using adenosine and purino receptor antagonists
US5874420A (en) 1995-12-26 1999-02-23 Allegheny University Of The Health Sciences Process for regulating vagal tone
EP1011686B9 (en) * 1997-03-25 2011-02-09 Duska Scientific Co Modulation of human mast cell activation

Also Published As

Publication number Publication date
JP2001518118A (ja) 2001-10-09
EP1011686A1 (en) 2000-06-28
EP1011686B1 (en) 2010-06-09
WO1998042353A1 (en) 1998-10-01
CA2288821C (en) 2008-10-14
AU7098598A (en) 1998-10-20
CA2288821A1 (en) 1998-10-01
US6465441B2 (en) 2002-10-15
US6372724B1 (en) 2002-04-16
AU741713B2 (en) 2001-12-06
EP1011686B9 (en) 2011-02-09
US20020055515A1 (en) 2002-05-09
EP1011686A4 (en) 2003-03-19
ATE470441T1 (de) 2010-06-15
DK1011686T3 (da) 2010-10-11

Similar Documents

Publication Publication Date Title
DE69841711D1 (de) Modulator der menschlichen mastzellaktivierung
DE69535328D1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
ATE510551T1 (de) Hemmung von gs-fdh zur modulierung der no- bioaktivität
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
TR199902803T2 (xx) VCAM-1' in te�hisinin daralt�lmas� i�in bile�ikler ve metodlar.
PT1017692E (pt) 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep)
WO2003103575A3 (en) Compounds, compositions, and methods
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
DE69620458D1 (de) Benzofuran-carboxamide und -sulfonamide
ATE352639T1 (de) Antisense modulation der expression von integrin alpha 4
DE69835288D1 (de) Kombinationstherapie zur modulation der humanen sexualreaktion
MXPA03010634A (es) Uso de inhibidores de proteasoma para tratar trastornos del ojo seco.
NO20052267L (no) Forbindelser, Preparater og Metoder
ATE342062T1 (de) Angiotensin ii zur verbesserung der befruchtung
ES2039578T3 (es) Procedimiento para producir mercapto-acilaminoacidos antihipertensivos.
WO2004053144A3 (en) Modulation of stem cell differentiation by modulation of caspase-3 activity
MXPA02004699A (es) Derivados de acidos hidroxieicosatetraenoico modificados con cadena omega y metodos de su uso para el tratameinto del ojo reseco.
WO2003049683A3 (en) Use of parapox b2l protein to treat cancer and modify immune responses
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
DE60028750D1 (de) Verwendung von tagatose zur verbesserung wichtiger blutfaktoren
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
WO2004015072A3 (en) Mrbs as modifiers of the rb pathway and methods of use
WO2003052070A3 (en) Vps41s as modifiers of cell death and methods of use